Study Shows That Immune Cells May Help Identify Patients With High-Risk Smoldering Myeloma Most Likely to Benefit From Treatment

Cross Center Single-Cell Rna Sequencing Study of The Immune Microenvironment in Rapid Progressing Multiple Myeloma

Dyadic Perspectives on Multiple Myeloma-Related Healthcare Access Barriers

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX)

Teclistamab in the Treatment of Relapsed or Refractory Multiple Myeloma

Immune Dysfunctions Affecting Bone Marrow Vγ9Vδ2 T Cells in Multiple Myeloma: Role of Immune Checkpoints and Disease Status

Quadruplet Produces Deep Responses in High-Risk, Newly Diagnosed Multiple Myeloma

Early Cytopenias and Infections After Standard of Care Idecabtagene Vicleucel in Relapsed or Refractory Multiple Myeloma

Study Shows That Immune Cells May Help Identify Patients With High-Risk Smoldering Myeloma Most Likely to Benefit From Treatment

header-info

Nov, 22, 2022

For many patients who have smoldering myeloma, early treatment can slow or delay the disease’s progression to multiple myeloma, according to a new study published by Sklavenitis-Pistofidis et al in Cancer Cell.